Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pracinostat is a potent histone deacetylase inhibitor with antitumor activity in both solid tumor and acute myeloid leukemia (AML) cell lines. Pracinostat is reported to have modest clinical activity in patients with advanced solid tumors. Given the higher preclinical sensitivity of hematologic malignancies to pracinostat, the authors conducted a phase 1 study to assess the safety, maximum tolerated dose, recommended phase 2 dose, efficacy, pharmacokinetics, and pharmacodynamics of pracinostat in patients with advanced hematological malignancies. METHODS: Pracinostat was administered orally 3 times a week for 3 weeks on a 28‐day cycle. Patients were assigned to 7 dose levels using a 3 + 3 dose escalation design. RESULTS: A total of 44 patients were enrolled, 25 of whom had AML and 14 of whom had myelodysplastic syndrome. The maximum tolerated dose was 120 mg and the recommended phase 2 dose was 60 mg. Two patients with AML achieved a response: 1 complete remission (CR) and 1 complete cytogenetic response. Despite a dose‐dependent increase in the plasma concentration of pracinostat, a similar increase in histone acetylation was not observed. As an extension, 10 additional patients with myelodysplastic syndrome were enrolled to assess the safety and efficacy of pracinostat in combination with azacitidine. Six patients achieved a CR and 3 achieved a CR without platelet recovery with no added toxicity. CONCLUSIONS: The results of the current study demonstrate that pracinostat is safe, with modest single‐agent activity in patients with hematological malignancies. Cancer 2017;123:4851‐9. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · cited 1×
“ventricular ejection fraction 50%); and no clinically significant comorbidities.(14) Major exclusion criteria were central nervous system involvement, concomitant treatment with other HDACIs, malabsorption, use of hydroxyurea or any investigational agent within 14 days”
BackgroundHistone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HDAC inhibitors (HDACIs) can reactivate gene expression and promote cell-cycle arrest, differentiation, and apoptosis through the induction of histone acetylation resulting in chromatin relaxation increasing the accessibility of transcription factors to their target genes.(1,5,8,9) Pracinostat, 3-(2-butyl-1-(2-diethyl…”
BackgroundInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 3×
“HDAC inhibitors (HDACIs) can reactivate gene expression and promote cell-cycle arrest, differentiation, and apoptosis through the induction of histone acetylation resulting in chromatin relaxation increasing the accessibility of transcription factors to their target genes.(1,5,8,9) Pracinostat, 3-(2-butyl-1-(2-diethyl…”
BackgroundDombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165 · cited 1×
“1 months, which compares favorably with the historic AZA data.(34) The results of the current study confirm the safety and efficacy of pracinostat in patients with advanced hematological malignancies, with significant activity noted among patients with AML and MDS, especially in combination with AZA.”
ResultGarcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104 · cited 2×
“Based on these results, two phase 2 studies have been conducted to determine the efficacy of this combination in both patients with higher-risk MDS and AML.(32,33) Despite the lack of efficacy noted in patients with higher-risk MDS due to a high rate of early discontinuation because of toxicity, there was significant…”
ResultInfluentialSelf-citation
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 78
Self-citation
Metadata
- Authors
- Abaza, Y. M., Kadia, T. M., Jabbour, E. J., Konopleva, M. Y., Borthakur, G., Ferrajoli, A., Estrov, Z., Wierda, W. G., Alfonso, A., Chong, T. H., Chuah, C., Koh, L., Goh, B., Chang, J. E., Durkes, D. E., Foudray, M. C., Kantarjian, H. M., Dong, X. Q., & Garcia‐Manero, G.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2017-08-25
- Volume
- 123
- Issue
- 24
- Pages
- 4851-4859
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2745555207
- Cited by
- 58
- References
- 8
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. https://app.cochat.ai/papers/10.1002/cncr.30949
- The paper
- Abaza, Y. M., Kadia, T. M., Jabbour, E. J., Konopleva, M. Y., Borthakur, G., Ferrajoli, A., Estrov, Z., Wierda, W. G., Alfonso, A., Chong, T. H., Chuah, C., Koh, L., Goh, B., Chang, J. E., Durkes, D. E., Foudray, M. C., Kantarjian, H. M., Dong, X. Q., & Garcia‐Manero, G. (2017). Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. https://doi.org/10.1002/cncr.30949
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.